EPCAM and neoplasm: Measurement of CTCs in the blood of metastatic breast cancer (MCB) patients was performed using EpCAM-specific antibodies for the enrichment of rare circulating tumor cells, which were subsequently further characterized by the expression of cytokeratins, presence of a nucleus, and lack of white blood cell marker CD45.